- Home
- GALT vs SRV Comparison
GALT vs SRV Comparison
Compare GALT & SRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GALT | SRV |
|---|---|---|
| Founded | 2000 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 203.7M | 180.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | GALT | SRV |
|---|---|---|
| Price | $3.54 | $39.60 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $8.50 | N/A |
| AVG Volume (30 Days) | ★ 510.8K | 33.9K |
| Earning Date | 11-14-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 13.38% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.11 | $30.73 |
| 52 Week High | $7.13 | $44.30 |
Technical Indicators
Market Signals| Indicator | GALT | SRV |
|---|---|---|
| Relative Strength Index (RSI) | 42.75 | 45.85 |
| Support Level | $2.93 | $39.10 |
| Resistance Level | $3.27 | $40.69 |
| Average True Range (ATR) | 0.29 | 0.68 |
| MACD | 0.05 | 0.05 |
| Stochastic Oscillator | 43.79 | 42.05 |
Price Performance
Historical ComparisonAbout GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
About SRV NXG Cushing Midstream Energy Fund of Beneficial Interest
NXG Cushing Midstream Energy Fund is a non-diversified, closed-end management investment company with an investment objective of seeking a high after-tax total return from a combination of capital appreciation and current income. The fund invests at least 80% of its net assets, plus any borrowings for investment purposes, in midstream energy investments.